Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 - Oculis Holding ( NASDAQ:OCS )
ZUG, Switzerland, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Oculis Holding AG OCS ( "Oculis" ) , a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that an update on the DIAMOND Phase 3 program with OCS-01, an OPTIREACH® formulation of high ...
| Ticker |
Sentiment |
Impact |
|
AON
|
Neutral
|
17 %
|
|
OCS
|
Somewhat Bullish
|
49 %
|
